Year 2016, Volume 17, Issue 2, Pages 77 - 83 2016-04-05

Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü

Salih NEMLİ [1] , Tuna DEMİRDAL [2]

241 774

Coronavirüsler zarflı, tek zincirli pozitif RNA virüsleri olup, genellikle üst solunum yolu enfeksiyonlarına sebep olurlar. 2012 yılıda Arap Yarımadası’nda ciddi akut solunum yetmezliği ile seyreden hastalarda yeni bir coronavirüs türü izole edilmiştir. Middle East Respiratory Syndrome-coronavirus (MERS-CoV) olarak adlandırılmıştır. Asemptomatik hastalıktan, ağır pnömoni, çoklu organ yetmezliği ve ölüme kadar ilerleyebilen çeşitli klinik şekillere sebep olabilir. Patojene özgül bir tedavi bulunmamaktadır. MERS-CoV ile enfekte olan hastalarda enfeksiyon kontrol önlemlerinin uygulanması virüsün yayılımının önlenmesi açısından önemli bir yer tutar.
Koronavirus, MERS, enfeksiyon
  • Lu R, Yu X, Wang W, et al. Characterization of human coronavirus etiology in Chinese adults with adults with acute upper respiratory tract infection by real-time RT-PCR assays. PLoS One 2012;7(6):e38638.
  • Al-Tawfiq JA. Middle East respiratory syndrome- coronavirus infection: an overview. J Infect Public Health 2013;6(5):319-22.
  • Holmes KV, Dominguez SR. The new age of virus discovery: genomic analysis of a novel human betacoronavirus isolated from a fatal case of pneumonia. MBio. 2013 8;4(1):e00548-12.
  • Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD,Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20.
  • Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013;67(2):130-40. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome corona-virus (MERS-CoV); announcement of the Coronavirus Study Group. J Virol 2013;87(14):7790-2.
  • The WHO MERS-CoV Research Group. State of Knowledge and data gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in humans. PLoS Curr 2013;5 pii: ecurrents. outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
  • Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495(7440):251-4.
  • Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013;500(7461):227-31.
  • Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl- peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40(3):209-94.
  • Hajjar SA, Memish ZA, McIntosh K. East Respiratory Syndrome Coronavirus (MERS-CoV): A Perpetual Challenge. Ann Saudi Med 2013;33(5):427-36.
  • WHO (2012-2013) World Health Organization. Global alert and response. Middle East respiratory syndrome coronavirus (MERS- CoV) update http://www.who.int/csr/don/2013_11_04/en/index. html Erişim Tarihi: 30.11.2013
  • Bermingham A, Chand MA, Brown CS, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012;17(40):20290.
  • Hijawi B, Abdallat M, Sayaydeh A, et al. Novel coronavirus infections in Jordan, April 2012: Epidemiological findings from a retrospective investigation. East Mediterr Health J ;19(Suppl 1):S12-8.
  • European Centre for Disease Prevention and Control. Epidemiological update: Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.ecdc.europa.eu/en/ press/news/_layouts/forms/News_DispForm.aspx?List=8db7286c- fe2d-476c-9133-f4cb1b568&ID=913&RootFolder=%2Fen%2Fpres s%2Fnews%2FLists%2FNews&Source=http%3A%2F%2Fwww%2
  • Eecdc%2Eeuropa%2Eeu%2Fen%2Fhealthtopics%2Fcoronavirus- infections%2FPages%2Fnews_and_epidemiological_ updates%2Easpx&Web=86661a14-fb61-43e0-9663-0d514841605d Erişim Tarihi: 04.12.2013
  • Korukluoğlu G, İnfluenza virüsu/solunum yolu virüsleri 2013 sezonu laboratuvar çalışmaları. http://www.klimik. org.tr/wp-content/uploads/2013/10/GÜLAY-KORUKLUOĞLU
  • Ekim-2013-1.pdf Erişim Tarihi: 04.12.2012
  • CDC. Morbidity and Mortality Weekly Report(MMWR). Update: Severe respiratory illness associated with Middle East Respiratory Syndrome Coronavirus (MER S-CoV) worldwide, –2013. MMWR Morb Mortal Wkly Rep 2013;62(23):480-3.
  • Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lanet Infect Dis 2013;13(9):752-61.
  • Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: The “knowns” and “unknowns”. J Formos Med Assoc 2013;112(7):372-81.
  • Reusken C, Mou H, Godeke GJ, et al. Specific serology for emerging human coronaviruses by protein microarray. Euro Surveill 2013;18(14):20441.
  • Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis :13(9):745–51. CDC. Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Version 2. http://www.cdc.gov/coronavirus/mers/guidelines- clinical-specimens.html Erişim Tarihi: 30.11.2013
  • WHO (2012-2013) World Health Organization. Global Alert and Response Revised interim case definition for reporting to
  • WHO – Middle East respiratory syndrome coronavirus (MERS- CoV) Interim case definition as of3 July 2013. www.who.int/csr/ disease/coronavirus_infections/case_definition/en/index.html Erişim Tarihi: 30.11.2013 de Wilde AH, Raj VS, Oudshoorn D, et al. MERS – coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A orinterferon-α treatment. J Gen Virol 2013;94(Pt 8):1749-60.
  • Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study. Hong Kong Med J ;9(6):399–406. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV- infected rhesus macaques. Nat Med 2013;19(10):1313-7.
  • Gierer S, Bertram S, Kaup F, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013;87(10):5502-11.
  • Mou H, Raj VS, van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013;87(16):9379-83.
  • Du L, Zhao G, Kou Z, et al. Identification of a receptor-binding domain in the s protein of the novel human coronavirus Middle Eastrespiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013;87(17):9939-42.
  • Assiri A, Mc Geer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med ;369(5):407-16. CDC. Interim infection prevention and control recommendations for hospitalized patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV). http://www. cdc.gov/coronavirus/mers/infection-prevention-control.html Erişim Tarihi: 30.11.2013
  • World Health Organization. Infection prevention and control during health care for probable or confirmed cases of novel coronavirus (nCoV) infection Interim guidance: 6 May http://www.who.int/csr/disease/coronavirusinfections/ IPCnCoVguidance 06May13.pdf Erişim Tarihi: 30.11.2013
  • CDC. Updated information on the epidemiology of Middle East Respiratory Syndrome Coronavirus(MER S-CoV) Infection and guidance for the public, clinicians, and Public Health Authorities,2012–2013. 2013:62(38);793-6.
  • Lu L, Liu Q, Du L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread, Microbes Infect 2013;15(8-9):625-9.
Primary Language en
Journal Section Review
Authors

Author: Salih NEMLİ

Author: Tuna DEMİRDAL

Dates

Publication Date: April 5, 2016

Bibtex @ { kocatepetip182724, journal = {Kocatepe Tıp Dergisi}, issn = {1302-4612}, eissn = {2149-7869}, address = {Afyonkarahisar Sağlık Bilimleri Üniversitesi}, year = {2016}, volume = {17}, pages = {77 - 83}, doi = {10.18229/ktd.04518}, title = {Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü}, key = {cite}, author = {NEMLİ, Salih and DEMİRDAL, Tuna} }
APA NEMLİ, S , DEMİRDAL, T . (2016). Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü. Kocatepe Tıp Dergisi, 17 (2), 77-83. Retrieved from http://dergipark.org.tr/kocatepetip/issue/17442/182724
MLA NEMLİ, S , DEMİRDAL, T . "Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü". Kocatepe Tıp Dergisi 17 (2016): 77-83 <http://dergipark.org.tr/kocatepetip/issue/17442/182724>
Chicago NEMLİ, S , DEMİRDAL, T . "Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü". Kocatepe Tıp Dergisi 17 (2016): 77-83
RIS TY - JOUR T1 - Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü AU - Salih NEMLİ , Tuna DEMİRDAL Y1 - 2016 PY - 2016 N1 - DO - T2 - Kocatepe Tıp Dergisi JF - Journal JO - JOR SP - 77 EP - 83 VL - 17 IS - 2 SN - 1302-4612-2149-7869 M3 - UR - Y2 - 2019 ER -
EndNote %0 Kocatepe Medical Journal Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü %A Salih NEMLİ , Tuna DEMİRDAL %T Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü %D 2016 %J Kocatepe Tıp Dergisi %P 1302-4612-2149-7869 %V 17 %N 2 %R %U
ISNAD NEMLİ, Salih , DEMİRDAL, Tuna . "Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü". Kocatepe Tıp Dergisi 17 / 2 (April 2016): 77-83.
AMA NEMLİ S , DEMİRDAL T . Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü. KTD. 2016; 17(2): 77-83.
Vancouver NEMLİ S , DEMİRDAL T . Ortadoğu Solunum Yetmezliği Sendromu Koronavirüsü. Kocatepe Tıp Dergisi. 2016; 17(2): 83-77.